Integrated multi-mechanism oral delivery architecture for the metabolic-peptide class at 3-to-5-kilodalton molecular weight, covering seven clinically relevant peptides: semaglutide (Novo GLP-1 RA, 4113. 58 Da), liraglutide (Novo GLP-1 RA, 3751. 20 Da, US composition-of-matter expired August 2025), tirzepatide (Lilly GLP-1/GIP dual agonist, 4813. 48 Da), exenatide (AstraZeneca GLP-1 RA, 4186. 57 Da, US composition-of-matter expired 2017), cagrilintide (Novo amylin analog, 4409. 01 Da), retatrutide (Lilly GLP-1/GIP/glucagon triple agonist, 4731. 33 Da), and survodutide (Boehringer Ingelheim and Zealand GLP-1/glucagon dual agonist, 4231. 63 Da). The architecture addresses four concurrent absorption barriers: luminal proteolytic stability against pepsin, trypsin, and chymotrypsin at gastric and duodenal pH; diffusion across an 80-micrometer adherent mucus gel with 100-to-500-nanometer mesh spacing; transepithelial crossing across a gastric-corpus or duodenal columnar monolayer with transepithelial electrical resistance approximately 1000 ohm square centimeters; and first-pass hepatic retention. Six coordinated subsystems within a single immediate-release tablet: salcaprozate sodium (SNAC) at 250 to 500 milligrams for transcellular hydrophobization via the Buckley 2018 and Colston 2025 quicksand mechanism; choline-and-geranate (CAGE) ionic liquid at 30 to 80 milligrams for paracellular tight-junction modulation (13-fold Caco-2 4-kilodalton dextran flux enhancement, 40-to-50-percent transepithelial electrical resistance reduction, Banerjee 2018), mucus fluidization, and peptide-hydration-shell water-activity reduction; a selective tight-junction modulator (PIP640 decapeptide analog or low-molecular-weight chitosan) at 2 to 10 milligrams; a 50-to-200-nanometer PLGA-PEG-2kDa mucus-penetrating nanoparticle carrier co-encapsulating peptide and SNAC at pH-5-triggered acetal disassembly (Ensign 2012 mucus-penetrating-particle design rules preserved) ; a thiolated chitosan mucoadhesive outer matrix at 20 to 50 milligrams; and standard pharmaceutical excipients. Tablet mass at or above 650 milligrams, SNAC strictly below 50 percent weight per weight, bulk density strictly below 1. 0 grams per cubic centimeter, disintegration time strictly above 22 minutes; each boundary places the composition strictly outside the independent-claim space of Novo Nordisk WO 2013/189988 and its US 9, 993, 430 and US 11, 033, 499 continuations. The transcellular and paracellular routes are physically orthogonal across the same epithelial monolayer and combine additively on Fₑpithelium without cross-interference, producing a route-additive absorption architecture not previously disclosed at the three-kilodalton-to-five-kilodalton lipidated or unlipidated metabolic-peptide payload. Predicted human oral bioavailability across the class is 4 to 14 percent theoretical nominal 8. 6 percent across the literature-anchored parameter band, and 2 to 7 percent effective pre-bench nominal 3. 6 percent after applying translation penalties for CAGE gastric-pH ionic-liquid state (geranic acid pKa approximately 5. 2) and sub-Banerjee local concentration and gastric-corpus versus Caco-2 claudin profile differences, versus approximately 1 percent for published Rybelsus. Per-peptide oral daily-dose envelopes at nominal bioavailability: semaglutide 0. 1 to 7. 5 milligrams; liraglutide 0. 25 to 75 milligrams; tirzepatide 0. 25 to 75 milligrams; exenatide 0. 01 to 7. 5 milligrams (pulsed-field co-primary due to unlipidated backbone and 2. 4-hour plasma half-life) ; cagrilintide 0. 125 to 15 milligrams monotherapy or 3-milligram-plus-3-milligram oral CagriSema co-tablet; retatrutide 0. 25 to 75 milligrams; survodutide 0. 1 to 30 milligrams. A secondary embodiment replaces the tablet with a pulsed-field ingestible capsule operating at 10 to 300 kilohertz frequency, 0. 1 to 25 volts per centimeter bulk-field amplitude, 1 to 100 millisecond pulse duration, 0. 1 to 10 percent duty cycle, 2 to 10 millimeter electrode separation, for device-assisted absorption enhancement via a sub-electroporative iontophoretic-drift mechanism; disclosed as co-primary for unlipidated exenatide per Claim 40 and Claim 81. A Mitragotri-independent variant for each peptide omits CAGE entirely and substitutes augmented selective tight-junction modulation plus trimethyl chitosan, preserving the route-additive architecture without dependency on Harvard / Cage Bio WO 2019/099837 CAGE licensing. Dedicated per-peptide Plan B claims are drafted for the two peptides with expired composition-of-matter status: Claim 22-bis for liraglutide (expired August 2025, generic available) and Claim 43-bis for exenatide (expired 2017, Amneal generic launched November 2024). The integrated disclosure comprises 15 numbered sections. § 11 carries a 108-integer-numbered-claim matrix: 100 primary claims (independent architecture Claim 1; per-peptide species Claims 9 through 69; process Claims 70 to 78; pulsed-field device Claims 79 to 88; combination co-tablet Claims 89 to 100), 6 § 11. 6 Component C ionic-liquid analog species claims (Claims 101 to 106: CAOT, choline-decanoate, choline-laurate, choline-oleate, betaine-based deep-eutectic-solvent, broad-ratio), and 2 bis claims (22-bis liraglutide Mitragotri-independent, 43-bis exenatide Mitragotri-independent). § 10. 5 adds a structural derivation of route-additivity from cubic-packing symmetry: Fₜranscellular places on the four-fold face-rotation rung at 4α, Fₚaracellular places on the twelve-edge enumeration rung at 12α with α the fine-structure constant, and the topological orthogonality of faces and edges under the octahedral group Oₕ supports the additive combination Fₑpithelium = Fₜranscellular + Fₚaracellular within ±10 percent of measured and disclosed values. § 12 enumerates nine variant families. § 13 enumerates ten anticipate-and-preempt subject-matter clusters. § 15 is a discretionary follow-on defensive-publication statement under 35 U. S. C. §102, with no committed schedule and no monitoring obligation. Published as defensive publication under 35 U. S. C. §102. Companion research note "Oral metabolic-peptide class delivery and the route-additive absorption problem" describes the same subject matter in a narrative register. Full numerical audit (353 items, 100 percent OK), freedom-to-operate 12-section element-by-element claim chart per peptide against patent families of Novo, Lilly, BI/Zealand, AstraZeneca, Harvard/Cage Bio (WO 2019/099837 Mitragotri claim 22 construction analysis per peptide), Rani, MIT/BWH (SOMA), Emisphere, Oramed, and Hanes mucus-penetrating particles; thirty-four pre-scoped adversarial attacks with responses; pharmacokinetic simulation code for six peptides; and the full master reference list included as supplementary materials.
Coracle Research (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: